Connor, Clark & Lunn Investment Management (CC&L)
CRVS icon

Connor, Clark & Lunn Investment Management (CC&L)’s Corvus Pharmaceuticals CRVS Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.23M Buy
83,907
+55,790
+198% +$890K ﹤0.01% 1109
2025
Q4 		$217K Buy
+28,117
New +$222K ﹤0.01% 1442
2024
Q4 		– Sell
-137,031
Closed -$724K – 1437
2024
Q3 		$724K Buy
137,031
+53,809
+65% +$193K ﹤0.01% 981
2024
Q2 		$151K Sell
83,222
-4,786
-5% -$8.92K ﹤0.01% 1285
2024
Q1 		$157K Buy
88,008
+16,800
+24% +$35.1K ﹤0.01% 1426
2023
Q4 		$125K Buy
71,208
+325
+0.5% +$475 ﹤0.01% 1303
2023
Q3 		$103K Sell
70,883
-13,485
-16% -$28.5K ﹤0.01% 1289
2023
Q2 		$193K Buy
+84,368
New +$175K ﹤0.01% 1194
2020
Q3 		– Sell
-84,918
Closed -$231K – 957
2020
Q2 		$231K Sell
84,918
-686
-0.8% -$2.03K ﹤0.01% 879
2020
Q1 		$181K Buy
85,604
+3,804
+5% +$15.4K ﹤0.01% 878
2019
Q4 		$445K Buy
81,800
+7,075
+9% +$24.7K ﹤0.01% 682
2019
Q3 		$225K Buy
74,725
+10,400
+16% +$43.6K ﹤0.01% 841
2019
Q2 		$241K Buy
64,325
+5,374
+9% +$21.1K ﹤0.01% 867
2019
Q1 		$237K Buy
58,951
+9,101
+18% +$38.4K ﹤0.01% 794
2018
Q4 		$183K Buy
49,850
+1,600
+3% +$10.9K ﹤0.01% 860
2018
Q3 		$414K Buy
48,250
+650
+1% +$6.5K ﹤0.01% 734
2018
Q2 		$523K Buy
47,600
+2,900
+6% +$32.4K ﹤0.01% 757
2018
Q1 		$515K Buy
44,700
+12,900
+41% +$122K ﹤0.01% 565
2017
Q4 		$329K Buy
31,800
+4,700
+17% +$60.2K ﹤0.01% 671
2017
Q3 		$432K Buy
27,100
+4,700
+21% +$65K ﹤0.01% 656
2017
Q2 		$271K Buy
+22,400
New +$239K ﹤0.01% 692

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s CRVS Position: Q1 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) increased its Corvus Pharmaceuticals (CRVS) stake by 198% in Q1 2026, buying an estimated $890K and bringing the position to 83,907 shares worth $1.23M. The position accounts for ﹤0.01% of the portfolio, ranked #1109.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in CRVS in Q2 2017 and has held it in 21 quarters since. 164 funds tracked by Wall St. Rank hold CRVS as of Q1 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 83,907 shares of Corvus Pharmaceuticals worth $1.23M as of Q1 2026.
  • Connor, Clark & Lunn Investment Management (CC&L) bought 55,790 Corvus Pharmaceuticals shares in Q1 2026, an estimated $890K.
  • Corvus Pharmaceuticals made up ﹤0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q1 2026, its #1109 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Corvus Pharmaceuticals in Q2 2017 and has held it in 21 quarters since.
  • 164 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q1 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2026, filed 11 May 2026.